Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT05513131 Recruiting - Clinical trials for Secondary Acute Myeloid Leukemia

Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML

Start date: September 30, 2021
Phase: Phase 2
Study type: Interventional

This research is being done to assess the therapeutic efficacy and safety of a promising regimen (Venetoclax combined with Azacitidine and Harringtonine) in patients with secondary AML This study involves the following: Venetoclax combined with Azacitidine and Harringtonine

NCT ID: NCT05510466 Recruiting - Metastatic Melanoma Clinical Trials

Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

Start date: January 1, 2019
Phase:
Study type: Observational

Currently, therapeutic options in BRAF mutated melanoma with brain metastasis occurring after achievement of a good control of extracerebral secondary lesions by a first line combined targeted therapy (TT) are limited. In this setting, the addition of an anti PD1 agent to TT may be proposed as a second line strategy. This observational survey aims at investigating the benefit/risk ratio of this triple combination in a small cohort of patients.

NCT ID: NCT05508464 Recruiting - Metastatic Cancer Clinical Trials

Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial

Start date: October 16, 2023
Phase: N/A
Study type: Interventional

This is a phase II/III international multicentre randomized trial. Patients will be randomized in a 1:2 ratio between the standard of care (Arm 1) and SABR (Arm 2) to all sites of disease. The study will start as a phase II trial with an opportunity to convert to a phase III trial. The objective of this trial is to determine the impact of SABR on overall survival, progression-free survival, quality of life, and toxicity in patients with polymetastatic disease.

NCT ID: NCT05495399 Recruiting - Spine Metastases Clinical Trials

Post Operative RT for Limited Spine Metastases

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

To evaluate patients with limited spine metastases treated with total spondylectomy followed by conventional radiotherapy or debulking surgery followed by SBRT or conventional RT. The study primary endpoint is one year local control.

NCT ID: NCT05485909 Recruiting - Clinical trials for Colorectal Cancer Liver Metastases

Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM

Start date: July 25, 2022
Phase: Phase 2
Study type: Interventional

The incidence of colorectal cancer liver metastasis is high and the prognosis is poor. Improving the treatment effect of colorectal cancer liver metastasis is the key to improving the prognosis of colorectal cancer patients. Rigofenib is one of the standard third-line treatments for advanced colorectal cancer, but has limited efficacy. Immune checkpoint inhibitors (PD-L1 monoclonal antibody, PD-1 monoclonal antibody) have achieved good results in the treatment of various malignant tumors. In a mouse transplant tumor model of colorectal cancer, regorafenib combined with PD-1 monoclonal antibody treatment significantly improved the antitumor activity, but the efficacy rate in clinical studies was not very high, especially for liver metastases. Radiofrequency ablation (RFA) is one of the common methods for the treatment of liver metastases. RFA may improve the immune microenvironment and the efficacy of immunotherapy,and the purpose of this trial is to explore the efficacy and safety of rigofenib and terepliumab combined with RFA in patients with refractory colorectal cancer liver metastasis.

NCT ID: NCT05485753 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Start date: February 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, the safety and preliminary efficacy of GNC-038 in patients with r relapsed or refractory primary central nervous system lymphoma (PCNSL) and relapsed or refractory secondary central nervous system lymphoma (SCNSL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-038. The recommended dose for phase II (RP2D) clinical study will also be determined.

NCT ID: NCT05485038 Recruiting - Glioma, Malignant Clinical Trials

General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas

GAMMA
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Objective of the study is to determine whether resection of gliomas and metastases of motor areas using awake surgery can achieve rarer motor deterioration after operation than using general anesthesia.

NCT ID: NCT05482529 Recruiting - Colorectal Cancer Clinical Trials

Integrative Omics Analysis for Colorectal Cancer and Metastasis

Start date: August 1, 2022
Phase:
Study type: Observational [Patient Registry]

The pathogenesis of Colorectal cancer (CRC) metastasis remains unclear.We collect clinical data from our center and use Integrative omics to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.

NCT ID: NCT05481658 Recruiting - Clinical trials for Cutaneous Metastases

Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases

Start date: October 6, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune checkpoint inhibition (ICI), compared to pre-treatment cutaneous metastases and to describe the adverse events associated with DPCP when administered topically twice weekly for 12 weeks in combination with PD-1 or PD-L1 ICI.

NCT ID: NCT05477927 Recruiting - Malignant Ascites Clinical Trials

Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases

Start date: November 28, 2023
Phase: Phase 1
Study type: Interventional

Serosal cavity metastases of malignant tumor seriously affects the quality of life and survival time of patients with cancers in advanced stage. VEGFR1 is frequently expressed in breast cancer, ovarian cancer, lung cancer, gastric cancer and other malignant tumors and their metastases. The VEGFR1/PD-L1 dual-targeting CAR-T will be investigated in cancer patients with serosal cavity metastases.